Clinical TrialMay 12, 2026, 09:33 AM
Cellectis to Present BALLI-01 & NATHALI-01 Data at EHA
AI Summary
Cellectis announced it will present data from its BALLI-01 and NATHALI-01 clinical trials at the European Hematology Association (EHA) annual congress in June 2026. The full Phase 1 dataset for lasme-cel (BALLI-01) in relapsed or refractory CD22+ B-cell acute lymphoblastic leukemia will be an oral presentation, highlighting promising safety and response rates, which forms the basis for the ongoing pivotal Phase 2 program. Preliminary analysis from the Phase 1 NATHALI-01 study for eti-cel in relapsed or refractory B-cell non-Hodgkin lymphoma will be a poster presentation, providing early mechanistic insights. Interim data for BALLI-01 and Phase 1 data for NATHALI-01 are both expected in Q4 2026.
Key Highlights
- Cellectis to present BALLI-01 and NATHALI-01 clinical trial data at the EHA congress in June 2026.
- Full Phase 1 dataset for lasme-cel (BALLI-01) in r/r CD22+ B-ALL selected for oral presentation.
- BALLI-01 data highlights promising safety profile and response rates in heavily pretreated patients.
- Pivotal Phase 2 program for BALLI-01 is currently recruiting in Europe and North America.
- First interim analysis for BALLI-01 is expected to be disclosed in Q4 2026.
- Preliminary analysis from Phase 1 NATHALI-01 study for eti-cel in r/r B-NHL accepted for poster presentation.
- NATHALI-01 data explores mechanistic insights into lymphodepletion regimen optimization.
- Phase 1 clinical data for NATHALI-01 is planned for disclosure in Q4 2026.